MarkWide Research - Global Market Intelligence Platform
Home›Industries›Healthcare›Diagnostics

Diagnostics Market Reports

Diagnostics encompasses the laboratories, imaging networks, and molecular testing platforms that convert biological specimens into actionable clinical intelligence. Laboratories process high-throughput assays across chemistry, hematology, and microbiology disciplines, while imaging centers deploy MRI, CT, and PET modalities for anatomical visualization. Point-of-care testing and companion diagnostics for targeted therapies are expanding addressable demand. Reimbursement mechanics and payer prior-authorization protocols heavily influence utilization patterns. Tightening regulatory perimeters around laboratory-developed tests are redrawing competitive lines between centralized health systems and independent reference labs.

310 Reports Found
France in-Vitro Diagnostics Market

The France in-Vitro Diagnostics Market sized at $3.9 Billion in 2026 is forecast to scale to $6.15 Billion by 2035, expanding at a 5.20% CAGR over the forecast window. Hospital-based laboratories across Île-de-France are deepening adoption of automated molecular diagnostics platforms. ANSM's strengthened post-market surveillance requirements for Class C and D IVD devices are accelerating manufacturer investment in clinical evidence generation. Demand is concentrating within oncology and infectious disease testing segments as precision medicine programs expand through regional hospital networks.

View More
Tissue Transglutaminase Test Market

The Tissue Transglutaminase Test Market valued at $487.6 Million in 2026 is projected to expand to $1,033.07 Million by 2035, advancing at a 8.70% CAGR over the analysis window. Diagnostic laboratories are scaling automated immunoassay platforms to handle rising celiac disease screening volumes. The FDA's evolving LDT oversight framework is reshaping test validation requirements for clinical laboratories. Demand concentrates in the United States, where high serological testing penetration and established reimbursement pathways sustain volume leadership.

View More
North America Autoimmune Disease Diagnostics Market

The North America Autoimmune Disease Diagnostics Market valued at $4.8 Billion in 2026 is projected to expand to $10.17 Billion by 2035, advancing at a 8.70% CAGR over the analysis window. Hospital laboratories are expanding their in-house autoimmune testing menus to reduce send-out costs. The FDA's evolving guidance on laboratory-developed tests is reshaping validation requirements for diagnostic platforms. Demand concentrates in the United States, where large integrated health systems drive volume consolidation for high-throughput autoimmune analyzers.

View More
Multiple Myeloma Diagnostics Market

The Multiple Myeloma Diagnostics Market valued at $1.8 Billion in 2026 is projected to expand to $3.81 Billion by 2035 growing at a CAGR of 8.70% through the forecast horizon. Hospital laboratories are expanding their in-house molecular testing capabilities. FDA breakthrough device designations and EMA accelerated assessment pathways are reshaping product commercialization timelines. Demand concentrates in the United States, Germany, and Japan where specialized oncology networks dominate referral patterns.

View More
Global Hepatitis Diagnostic Test Market

The Global Hepatitis Diagnostic Test Market valued at $4.1 Billion in 2026 is expected to reach $7.17 Billion by 2035 growing at a CAGR of 6.40% through the forecast horizon. Blood banks in the United States are expanding nucleic acid testing protocols under FDA guidance. The WHO prequalification program for in vitro diagnostics is accelerating technology transfer to low-income settings. Demand is concentrating in India, where the National Viral Hepatitis Control Program is scaling screening through public health agencies and diagnostic centers.

View More
Global Coagulation Analyzers Market

The Global Coagulation Analyzers Market valued at $4.6 Billion in 2026 is projected to expand to $8.32 Billion by 2035, advancing at a 6.80% CAGR over the analysis window. Hospital laboratories across North America and Europe are expanding automated coagulation testing capacity to manage rising surgical volumes and anticoagulant monitoring workloads. The EU In Vitro Diagnostic Regulation is accelerating instrument replacement cycles as legacy devices require recertification. Demand concentrates most acutely in the United States, where integrated health networks are consolidating laboratory services into centralized regional hubs.

View More
Fungal Antigens Market

The Fungal Antigens Market valued at $312.6 Million in 2026 is forecast to scale to $662.3 Million by 2035, progressing at a 8.70% CAGR throughout the forecast period. Clinical diagnostics laboratories in North America and Europe are expanding their use of fungal antigen detection kits for invasive aspergillosis and cryptococcal meningitis screening. The FDA's updated in vitro diagnostic guidance and the EU's In Vitro Diagnostic Regulation (IVDR) are tightening performance standards for serological assays, pushing manufacturers toward higher-sensitivity recombinant antigen production. Demand is concentrating most visibly in the United States, where hospital-acquired fungal infection surveillance programs and Medicare reimbursement policies for diagnostic testing create sustained procurement pull-through.

View More
In Vitro Diagnostic (IVD) Reagent Market

The In Vitro Diagnostic (IVD) Reagent Market valued at $68.4 Billion in 2026 is expected to reach $123.65 Billion by 2035 growing at a CAGR of 6.80% through the forecast horizon. Diagnostic laboratories are expanding automated testing platforms. The FDA's evolving guidance on laboratory-developed tests is reshaping product registration pathways. Demand concentrates in the United States, Germany, and China as these countries scale precision medicine infrastructure.

View More
Viral Disease Diagnosis Market

The Viral Disease Diagnosis Market valued at $52.7 Billion in 2026 is projected to expand to $110.73 Billion by 2035, advancing at a 8.60% CAGR over the analysis window. Diagnostic laboratories are expanding molecular testing capacity as FDA emergency use authorization pathways accelerate assay approvals. Demand concentrates in the United States, where hospital consolidation drives centralized procurement of multiplex PCR platforms.

View More
Vision Screeners Market

The Vision Screeners Market, valued at $412.5 Million in 2026, is projected to expand to $745.7 Million by 2035, advancing at a 6.80% CAGR over the analysis window. Growth is driven by expanded screening programs in schools. The integration of advanced retinal imaging technology into portable devices improves diagnostic accuracy and workflow efficiency. Demand concentrates in the United States, supported by state-level mandates for early childhood vision testing before school entry.

View More

Get Expert Help

Can't find what you need? Our analysts will help you locate or build the right report for your requirements.

Contact Our Team →